Kemwell will produce RO-104 for treating neovascular age-related macular degeneration. Credit: Jo Panuwat D/ Shutterstock.

RevOpsis Therapeutics has entered a strategic manufacturing collaboration with contract development and manufacturing organisation Kemwell Biopharma to accelerate the development of new multispecific biologics.

The deal speeds up the development of RevOpsis’ lead candidate, RO-104, a tri-specific biologic aimed at treating neovascular age-related macular degeneration (nAMD).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Kemwell will concurrently produce RO-104, an asset that can bind three validated targets implicated with nAMD.

The alliance will harness the manufacturing prowess of Kemwell alongside RevOpsis’ Rev-Mod platform, to streamline the development process for multispecific biologics.

RevOpsis will gain access to a biologics development solution, enabling a swift transition from pre-clinical works to first-in-human clinical trials to advance the development of RO-104 and the broader platform.

See Also:

Merging the plug-and-play multispecific biologics platform of RevOpsis with the deep biologics development and manufacturing expertise of Kemwell will aid the partnership to quicken the discovery of therapeutics and advance them to investigational new drug (IND) submission.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The partnership is designed to link preclinical works, process development and clinical production to lower the complexity and timelines typically associated with handling early Good Manufacturing Practices (GMP) processes.

RevOpsis co-founder and interim CEO Ram Bhandari said: “Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics.

“Kemwell’s exemplary track record in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies to patients efficiently. This collaboration aligns with our mission to develop groundbreaking treatments expeditiously, and bring our innovation to patients worldwide.”